A retrospective study (with no control group) conducted by Sawada et al. examined the effects of SGLT2 inhibitors on 18 T2D patients with OSA (12/18 with severe OSA) regarding weight reduction and changes in AHI. This evidence concerns the gene SLC5A2 and obstructive sleep apnea syndrome.